United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices
Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a...
Fineline Cube
Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has...
JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process
China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...
iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...
Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...
Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines
China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced additional indication approval from China’s National Medical Products...
AstraZeneca’s Ultomiris Approved in China for Generalized Myasthenia Gravis
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has announced that the National Medical Products Administration (NMPA)...
Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug...
Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder
Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan’s Ministry of...
Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has completed a private placement, raising RMB 1.796...
Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors
China-based Bio-Thera Solutions Inc. (SHA: 688177) has announced that it has received clinical approval from...
Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been...
Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...
China’s Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead
The first blue book on the reform of China’s medical insurance payment methods, titled “Report...
Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...
Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...
Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...
Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...